<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hashimoto encephalopathy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hashimoto encephalopathy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hashimoto encephalopathy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Devon I Rubin, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Aminoff, MD, DSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hashimoto encephalopathy (HE) is an uncommon syndrome associated with Hashimoto thyroiditis (HT). "Steroid-responsive encephalopathy associated with autoimmune thyroiditis" (SREAT) and a more general term, "nonvasculitic autoimmune meningoencephalitis," are also used to describe this condition. </p><p>Originally described in 1966, it remains a somewhat controversial disorder [<a href="#rid1">1</a>]. HE is most often characterized by a subacute onset of confusion with altered level of consciousness, seizures, and myoclonus. In contrast with the cognitive dysfunction associated with hypothyroidism or hyperthyroidism, HE is believed to be an immune-mediated disorder rather than representing the direct effect of an altered thyroid state on the central nervous system.</p><p>HE will be reviewed here. HT and other neurologic complications of thyroid disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7854.html" rel="external">"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)"</a> and  <a class="medical medical_review" href="/z/d/html/7822.html" rel="external">"Myxedema coma"</a> and  <a class="medical medical_review" href="/z/d/html/4841.html" rel="external">"Neurologic manifestations of hypothyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/4836.html" rel="external">"Neurologic manifestations of hyperthyroidism and Graves' disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The mechanism of HE is unknown. It does not appear to be directly related to hypothyroidism or hyperthyroidism, as the majority of reported patients are euthyroid at the time of presentation. A toxic effect of increased thyrotropin-releasing hormone on the central nervous system has been proposed, as some patients appear to improve with thyroid supplementation despite being euthyroid [<a href="#rid2">2-4</a>]. However, these cases appear to be the exception rather than the rule.</p><p>The bulk of evidence points to an autoimmune vasculitis or other inflammatory process, perhaps associated with immune complex deposition, and possibly disrupting the cerebral microvasculature [<a href="#rid2">2,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pathologic examination at autopsy or brain biopsy in a few patients has identified lymphocytic infiltration around small arterioles and venules [<a href="#rid3">3,6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with HE appear to respond to glucocorticoid therapy or other immunosuppressive therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The disorder is more common in women, as is true of most autoimmune disorders [<a href="#rid2">2-4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated antithyroid antibodies, an essential feature of this disorder, are consistent with an active autoimmune process.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one series, seven of eight patients had HLA B8 DRw3 haplotypes compared with 30 percent of a control population [<a href="#rid7">7</a>]. This profile is common to other patients with autoimmune diseases.</p><p></p><p>The nature of the relationship between Hashimoto thyroiditis (HT) and HE is unclear. Some argue that the association is entirely spurious [<a href="#rid8">8</a>]. Elevated antithyroid antibodies in the serum correlate well with pathologic thyroiditis. However, elevated titers are prevalent in the general healthy population, occurring in 2 to 10 percent of young adults and 5 to 20 percent of older adults. It is possible, therefore, that elevated titers are a coincidental finding.</p><p>Others argue that the relationship between HT and HE is just that seen among autoimmune disorders in general [<a href="#rid3">3</a>]. HT itself is associated with neurologic and systemic autoimmune diseases including myasthenia gravis, systemic lupus erythematosus, and type 1 diabetes mellitus [<a href="#rid7">7</a>]. Support for this argument includes the observation that the symptoms of HE are not paralleled by symptoms of thyroiditis. In addition, changes in antithyroid autoantibody levels do not consistently correspond with neurologic symptoms or improvement with treatment. These findings lead some to propose that steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) is a more appropriate designation for this disorder [<a href="#rid9">9-11</a>].</p><p>The nature of the putative autoimmune response in HE is speculative. A number of observations and investigations in small numbers of patients have elicited different theories:</p><p class="bulletIndent1"><span class="glyph">●</span>HE may result from a direct antibody-mediated neuronal injury. Immunohistochemical analysis in one patient with HE detected an antineuronal antibody that reacted with human cerebral cortex [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HE may represent a vasculitis that results from either endothelial inflammation or immune complex deposition. Findings of perfusion deficits on single-photon emission computed tomography (SPECT) suggest vascular involvement [<a href="#rid3">3,7,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A potentially specific marker for HE has been identified in an autoantibody expressed against the amino terminal end of the enzyme alpha enolase. In one study, reactivity was found in five of six HE patients compared with 2 of 17 patients with HT [<a href="#rid14">14</a>]. No reactivity was found either in 25 healthy controls or in 25 patients with other autoimmune or encephalopathic neurologic disorders. A pathogenic role for this antibody is not understood; however, as alpha enolase is expressed on endothelial cells, it may mediate a vasculitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HE may be a primary demyelinating process akin to acute disseminated encephalomyelitis (ADEM). This is corroborated by pathologic and magnetic resonance imaging (MRI) findings in a few patients with HE, which appear similar to those seen in ADEM [<a href="#rid3">3,15</a>]. However, MRI findings of white matter disease are not typical of most reported patients with HE. These ADEM-like cases may represent anomalous cases of acute demyelinating disease in patients with incidentally elevated antithyroid antibody levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HE may represent an immune complex disease, since immune complexes were found in the cerebrospinal fluid (CSF) in a series of six patients with HE [<a href="#rid16">16</a>]. However, CSF immunoglobulin G (IgG) indices are inconsistently elevated in HE. Also, the degree of inflammation on CSF analysis and neuroimaging appears mild in HE and therefore at odds with this pathogenesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It seems unlikely that the antithyroid antibodies play a pathogenic role in HE. There is no evidence of a central nervous system antigen recognized by these antibodies. On the other hand, antithyroid antibodies were identified in the CSF of all six of the patients with HE in one report and in none of the controls [<a href="#rid16">16</a>]. This, in the absence of blood-brain barrier disruption, suggests possible intrathecal synthesis of these antibodies. However, others have not found these antibodies to be reliably present in the CSF in patients with HE [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">RELATED DISORDERS</span></p><p class="headingAnchor" id="H4"><span class="h2">Nonvasculitic autoimmune inflammatory meningoencephalitis</span><span class="headingEndMark"> — </span>Less frequently reported than HE are similar syndromes in other autoimmune disorders (eg, Sjögren's disease) that have been labeled nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM) [<a href="#rid17">17-19</a>]. HE and NAIM are clinically similar and have similar diagnostic findings, suggesting that HE may be a subset of NAIM. A lymphocytic pleocytosis in the cerebrospinal fluid (CSF) is not, as one might expect from its name, a cardinal feature of NAIM and is also relatively uncommon among reported cases of HE. A steroid-responsive encephalopathy has been reported in one patient with Graves' disease, an autoimmune disorder that causes hyperthyroidism [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Acute disseminated encephalomyelitis</span><span class="headingEndMark"> — </span>Acute disseminated encephalomyelitis (ADEM) is an inflammatory, presumably autoimmune, demyelinating disease of the central nervous system. (See  <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>Some propose that HE is a form of ADEM. One series identified a high rate of possible provoking factors for HE, such as infection and surgery, which are also noted in ADEM [<a href="#rid7">7</a>]. Although a few reported cases of HE have similar MRI and pathologic findings to ADEM, most do not. It seems possible that these exceptional cases are in fact cases of ADEM with incidental elevations of antithyroid antibodies. Unlike HE, ADEM is a monophasic disorder and is not generally associated with other autoimmune diseases.</p><p class="headingAnchor" id="H6"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>A systematic review published in 2016 identified 251 published cases of HE [<a href="#rid21">21</a>]. The syndrome may be underrecognized [<a href="#rid2">2</a>]. A hospital-based epidemiologic study aggressively screened for HE in patients with unexplained neurologic symptoms consistent with HE and estimated the prevalence of HE to be 2.1 per 100,000 [<a href="#rid22">22</a>].</p><p>Among reported cases, the mean age of onset of initial symptoms is 51 years (range 9 to 86) [<a href="#rid2">2-4,21,23,24</a>]. Women are more commonly affected than men, at a ratio of approximately four to one.</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Clinical manifestations of HE most often include an acute to subacute onset of confusion with alteration of consciousness [<a href="#rid2">2,5</a>]. Two patterns of presentation have been described:</p><p class="bulletIndent1"><span class="glyph">●</span>A stroke-like pattern of multiple, recurrent, acute to subacute episodes of focal neurologic deficits with a variable degree of cognitive dysfunction and alteration of consciousness. Approximately 25 percent of patients follow this course [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A diffuse, progressive pattern, characterized by slowly progressive cognitive impairment with dementia, confusion, hallucinations, or somnolence [<a href="#rid2">2,25</a>]. Some cases have a more fulminant presentation in which rapid deterioration to coma occurs [<a href="#rid2">2,7</a>]. In one systematic review, 15 percent of patients presented in coma [<a href="#rid21">21</a>].</p><p></p><p>These clinical patterns can overlap. In addition to confusion and mental status changes, other neurologic signs are common in both groups:</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately two-thirds to one-half of patients experience focal or generalized tonic-clonic seizures [<a href="#rid3">3,21,23,26,27</a>]. Seizures are reported to be a presenting symptom in 47 percent of patients [<a href="#rid21">21</a>]. Status epilepticus has been reported in 25 percent [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myoclonus or tremor is seen in up to 38 percent of patients [<a href="#rid3">3,23</a>]. Myoclonus may be focal or multifocal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse hyperreflexia and other pyramidal tract signs are present in 85 percent of patients [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychosis, particularly visual hallucinations, but also paranoid delusions, have been reported in 25 to 36 percent of patients [<a href="#rid3">3,21,23</a>]. Approximately 10 to 25 percent of patients present with isolated psychiatric symptoms [<a href="#rid21">21,28</a>].</p><p></p><p>The long-term course of illness may be self-limited, relapsing-remitting, or progressive [<a href="#rid29">29,30</a>].</p><p>Rare syndromes associated with HE include a cerebellopathy with or without encephalopathy, isolated myelopathy, and chorea [<a href="#rid24">24,31-35</a>]. Peripheral nervous system involvement with electrophysiological evidence of a sensory ganglionopathy, demyelinating polyneuropathy, and/or amyotrophy has been described in individual cases of HE [<a href="#rid36">36-38</a>].</p><p>There are no systemic symptoms, including fever, with rare exceptions [<a href="#rid7">7</a>]. Neurologic symptoms can occur in patients with a known diagnosis of Hashimoto thyroiditis (HT) or in patients without a previous diagnosis. The development of clinical HT may occur up to three years after presentation with HE [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H8"><span class="h1">LABORATORY FEATURES</span></p><p class="headingAnchor" id="H9"><span class="h2">Antithyroid antibodies</span><span class="headingEndMark"> — </span>An elevated serum level of antithyroid peroxidase antibody (TPOAb) and/or antithyroglobulin antibody (TgAb) is an essential laboratory feature of HE. The median anti-TPOAb level at diagnosis was 900 international units/mL according to one review [<a href="#rid21">21</a>]. However, there is no clear relationship between the severity of neurologic symptoms and the type or serum concentration of antibodies; in addition, antibody levels may or may not decrease following treatment [<a href="#rid3">3,7,11,22,23</a>]. Given the prevalence of these antibodies in the general healthy population of 2 to 20 percent, this cannot be considered to be a specific finding for HE.</p><p>Antithyroid antibodies are infrequently measured in the cerebrospinal fluid (CSF). One case series found that 9 of 12 patients with encephalopathy and elevated serum antithyroid antibodies had elevated CSF autoantibody titers [<a href="#rid22">22</a>]. The authors suggested that serum antibody titers were overly sensitive. However, other investigators did not find antithyroid antibodies in the CSF of patients with HE [<a href="#rid5">5</a>]. The specificity and sensitivity of antithyroid antibodies in the CSF are unclear.</p><p class="headingAnchor" id="H10"><span class="h2">Thyroid hormone levels</span><span class="headingEndMark"> — </span>Thyroid status varies among patients with reported HE, ranging from overt hypothyroidism to overt hyperthyroidism. In systematic reviews, 23 to 35 percent of patients with HE have subclinical hypothyroidism and 17 to 25 percent have overt hypothyroidism [<a href="#rid3">3,23</a>]. Approximately 7 percent are hyperthyroid; the remainder are euthyroid [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Cerebrospinal fluid</span><span class="headingEndMark"> — </span>CSF analysis is abnormal in approximately 80 percent of patients [<a href="#rid2">2</a>]. The following findings have been noted [<a href="#rid2">2,21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The most common abnormality is an elevated protein concentration (reported range 48 to 298 mg/dL), which occurs in approximately 82 percent of patients. Levels greater than 100 mg/dL are uncommon, occurring in approximately 20 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lymphocytic pleocytosis (8 to 169 cells) is present in 10 to 25 percent of patients [<a href="#rid2">2,21,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The glucose concentration is normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both the presence and absence of oligoclonal bands are reported [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated 14-3-3 protein, a finding associated with Creutzfeldt-Jakob disease, has been reported in HE but is not a universal finding [<a href="#rid23">23,30,39</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Electroencephalography</span><span class="headingEndMark"> — </span>Nonspecific electroencephalographic (EEG) abnormalities are seen in 90 to 98 percent of patients, usually demonstrating nonspecific slowing of background activity [<a href="#rid2">2,7,9,40</a>]. Focal spikes or sharp waves and transient epileptic activity are less common. Triphasic waves and frontal intermittent rhythmic delta activity (FIRDA) have also been described.</p><p>Some report that EEG abnormalities recover rapidly with steroid administration [<a href="#rid9">9</a>], whereas others note that EEG improvement lags behind clinical improvement [<a href="#rid7">7,41</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>MRI in patients with HE is usually normal, but approximately half of patients may demonstrate cerebral atrophy or nonspecific T2 signal abnormalities in the subcortical white matter [<a href="#rid3">3,21</a>]. The latter have been described in approximately one-half of patients and do not enhance with gadolinium [<a href="#rid2">2,3,7</a>]. This may be an incidental finding, although a few reports have described regression or resolution of these findings with treatment [<a href="#rid3">3</a>].</p><p>In exceptional cases of HE, MRI findings of diffuse or focal white matter changes suggesting primary demyelination have been described [<a href="#rid3">3,15,42,43</a>]. Other findings noted in individual case reports include meningeal enhancement [<a href="#rid43">43</a>] and T2 signal abnormalities in both hippocampi [<a href="#rid42">42</a>].</p><p>Follow-up imaging is not often described. In some cases, the findings appear to regress or resolve with treatment [<a href="#rid3">3</a>].</p><p>Other tests also reveal nonspecific findings. Cerebral angiography, when performed, is normal [<a href="#rid2">2</a>]. Single-photon emission computed tomography (SPECT) may show focal, multifocal, or global hypoperfusion [<a href="#rid3">3,7,13</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Other</span><span class="headingEndMark"> — </span>C-reactive protein and the erythrocyte sedimentation rate are elevated in some patients [<a href="#rid43">43</a>]. In one series, mild elevations of liver enzymes were found in 12 of 20 patients [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H15"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Any disease associated with a syndrome of delirium or rapidly progressive dementia may be confused with HE. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Creutzfeldt-Jakob disease</p><p class="bulletIndent1"><span class="glyph">●</span>Acute disseminated encephalomyelitis (ADEM)</p><p class="bulletIndent1"><span class="glyph">●</span>Toxic metabolic encephalopathies (<a class="graphic graphic_table graphicRef59893" href="/z/d/graphic/59893.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Meningoencephalitis</p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric disease (depression, anxiety, psychosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Carcinomatous meningitis</p><p class="bulletIndent1"><span class="glyph">●</span>Paraneoplastic or autoimmune encephalitis</p><p class="bulletIndent1"><span class="glyph">●</span>Degenerative dementia (Alzheimer disease, dementia with Lewy bodies, frontotemporal dementia)</p><p class="bulletIndent1"><span class="glyph">●</span>Stroke or transient ischemic attack</p><p class="bulletIndent1"><span class="glyph">●</span>Basilar or hemiplegic migraine</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral vasculitis</p><p></p><p>The essential testing required to exclude these conditions is discussed in the subsequent section. (See <a class="local">'Diagnosis'</a> below.)</p><p>One study examined the clinical features of 32 patients presenting with progressive encephalopathy associated with elevated antithyroid antibody titers [<a href="#rid43">43</a>]. Of the 12 patients who did not respond to steroids, four with autopsy data were later proven to have alternative diagnoses: Creutzfeldt-Jakob disease, frontotemporal dementia, and dementia with Lewy bodies. Notably, these are all untreatable conditions.</p><p class="headingAnchor" id="H16"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The finding of elevated antithyroid peroxidase antibody (TPOAb) or antithyroglobulin antibody (TgAb) in patients with a compatible clinical presentation is required for the diagnosis of HE. These findings and a response to glucocorticoids generally define this syndrome. Thyroid hormone levels should be measured but, as noted above, thyroid status is variable in HE. (See <a class="local">'Thyroid hormone levels'</a> above.)</p><p>Essential testing to exclude other diagnoses includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Lumbar puncture to include cultures for bacteria, viruses, fungi, and mycobacterium</p><p class="bulletIndent1"><span class="glyph">●</span>EEG</p><p class="bulletIndent1"><span class="glyph">●</span>MRI with gadolinium administration</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing for usual causes of delirium (see  <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states", section on 'Diagnostic tests'</a>)</p><p></p><p>Because the treatment of HE consists of immunosuppressive therapy, it is especially important to thoroughly exclude infection. Other, less routine diagnostic test considerations should include cerebrospinal fluid (CSF) analysis for 14-3-3 protein (for possible Creutzfeldt-Jakob disease), CSF cytology, antibody testing for possible paraneoplastic or autoimmune encephalopathy, and screening for underlying neoplasm. (See  <a class="medical medical_review" href="/z/d/html/5185.html" rel="external">"Clinical features and diagnosis of leptomeningeal disease from solid tumors", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/5084.html" rel="external">"Creutzfeldt-Jakob disease", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>HE is usually treated with glucocorticoids and treatment of a dysthyroid state, if present. An optimal glucocorticoid dose has not been defined. Oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> doses ranging from 50 to 150 mg daily have been used [<a href="#rid2">2,21</a>]. According to one review, high-dose intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> was administered initially in 65 percent of reported patients (approximately one-third receiving 1 gram intravenous for three days) prior to oral prednisone, but a benefit compared with oral glucocorticoids is unknown. Spontaneous recovery is also reported, but most patients are treated if the syndrome is recognized [<a href="#rid21">21,22,40</a>]. </p><p>Symptoms typically improve or resolve over a few months. The duration of treatment and the rate of taper are generally titrated to the clinical response. In some patients, this is as long as two years.</p><p>While most patients (90 to 98 percent) respond to glucocorticoid therapy, recovery may be incomplete. In one series of 24 patients, only 32 percent obtained a complete response to steroids [<a href="#rid28">28</a>]. Response to glucocorticoids was not predicted by clinical features or antibody levels.</p><p>A small number (5 percent) of reported patients have been treated with other immunosuppressive medications, including <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [<a href="#rid5">5,7,21,44,45</a>]. These are generally reserved for patients who cannot tolerate glucocorticoids, or those who do not respond to or relapse after or during tapering of glucocorticoid therapy. Clinical improvement with intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> [<a href="#rid46">46,47</a>] and plasmapheresis [<a href="#rid48">48-51</a>] has been reported in individual cases.</p><p>Treatment of seizures with an antiseizure medication may be necessary as a temporary measure. In some patients, seizures do not respond to antiseizure medications but may respond to steroid therapy [<a href="#rid7">7</a>]. The management of acute symptomatic seizures is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults", section on 'Management'</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of HE is generally but not universally good; a complete or partial neurologic response has been reported in 93 percent of cases three months after the initial diagnosis [<a href="#rid21">21</a>]. While a delay to diagnosis and therefore treatment might be expected to be associated with less complete recovery, case series and reports suggest that patients can improve with treatment even after a few years of symptoms. However, residual cognitive impairment occurs in approximately 25 percent of patients with long-standing untreated disease [<a href="#rid7">7,40,43</a>].</p><p>Many patients remain in remission after discontinuation of steroids over several years of follow-up. However, relapses are reported in 16 percent of patients followed over a median follow-up time of 12 months (range 0.2 to 110 months) [<a href="#rid21">21</a>], and some patients require long-term immunosuppressive therapy [<a href="#rid7">7,43</a>].</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and definition</strong> – Hashimoto encephalopathy (HE) is a syndrome of acute or subacute encephalopathy that is associated with elevated antithyroid antibody titers. HE appears to be rare but may be underrecognized. As with Hashimoto thyroiditis (HT), women are more commonly affected than men. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – The bulk of evidence suggests that HE is an autoimmune disorder and is not due to thyroid disease. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The presentation is heterogeneous with a fulminant, subacute, or more chronic course of declining mental status that is frequently accompanied by seizures and myoclonus. Some patients present with coma and others with isolated psychiatric features. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – The presence of elevated antithyroid antibody titers and the exclusion of other causes of encephalopathy support the diagnosis of HE. While the entity of HE is disputed, there appears to be enough evidence to support checking antithyroid antibody levels as a second- or third-tier diagnostic test in patients presenting with unexplained encephalopathy and considering the diagnosis of HE if levels are elevated.</p><p></p><p class="bulletIndent1">Other test findings are nonspecific. Nonetheless, MRI, EEG, cerebrospinal fluid (CSF) analysis, and other laboratory studies are essential in these patients to exclude other causes of encephalopathy. (See <a class="local">'Differential diagnosis'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – In a patient with encephalopathy and elevated antithyroid antibody levels in whom other causes of encephalopathy are rigorously excluded, we suggest an initial trial of glucocorticoid therapy rather than other immunosuppressive therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Other immunosuppressive treatments have also been used in patients who cannot take glucocorticoids, who are refractory to glucocorticoids, or who relapse after initial treatment. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Most patients have a good outcome, but a significant minority have persistent cognitive deficits, particularly those with long-standing untreated disease. Relapses may require prolonged immunosuppressive therapy. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brain L, Jellinek EH, Ball K. Hashimoto's disease and encephalopathy. Lancet 1966; 2:512.</a></li><li><a class="nounderline abstract_t">Kothbauer-Margreiter I, Sturzenegger M, Komor J, et al. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol 1996; 243:585.</a></li><li><a class="nounderline abstract_t">Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol 2003; 60:164.</a></li><li><a class="nounderline abstract_t">Peschen-Rosin R, Schabet M, Dichgans J. Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease. Eur Neurol 1999; 41:79.</a></li><li><a class="nounderline abstract_t">Shaw PJ, Walls TJ, Newman PK, et al. Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers--report of 5 cases. Neurology 1991; 41:228.</a></li><li><a class="nounderline abstract_t">Duffey P, Yee S, Reid IN, Bridges LR. Hashimoto's encephalopathy: postmortem findings after fatal status epilepticus. Neurology 2003; 61:1124.</a></li><li><a class="nounderline abstract_t">Chaudhuri A, Behan PO. The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto's encephalopathy (recurrent acute disseminated encephalomyelitis). Curr Med Chem 2003; 10:1945.</a></li><li><a class="nounderline abstract_t">Sunil GS, Mariash CN. Hashimoto's encephalitis. J Clin Endocrinol Metab 2001; 86:947.</a></li><li><a class="nounderline abstract_t">Rodriguez AJ, Jicha GA, Steeves TD, et al. EEG changes in a patient with steroid-responsive encephalopathy associated with antibodies to thyroperoxidase (SREAT, Hashimoto's encephalopathy). J Clin Neurophysiol 2006; 23:371.</a></li><li><a class="nounderline abstract_t">Fatourechi V. Hashimoto's encephalopathy: myth or reality? An endocrinologist's perspective. Best Pract Res Clin Endocrinol Metab 2005; 19:53.</a></li><li><a class="nounderline abstract_t">Cantón A, de Fàbregas O, Tintoré M, et al. Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition? J Neurol Sci 2000; 176:65.</a></li><li><a class="nounderline abstract_t">Oide T, Tokuda T, Yazaki M, et al. Anti-neuronal autoantibody in Hashimoto's encephalopathy: neuropathological, immunohistochemical, and biochemical analysis of two patients. J Neurol Sci 2004; 217:7.</a></li><li><a class="nounderline abstract_t">Forchetti CM, Katsamakis G, Garron DC. Autoimmune thyroiditis and a rapidly progressive dementia: global hypoperfusion on SPECT scanning suggests a possible mechanism. Neurology 1997; 49:623.</a></li><li><a class="nounderline abstract_t">Fujii A, Yoneda M, Ito T, et al. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto's encephalopathy. J Neuroimmunol 2005; 162:130.</a></li><li><a class="nounderline abstract_t">Mahad DJ, Staugaitis S, Ruggieri P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci 2005; 228:3.</a></li><li><a class="nounderline abstract_t">Ferracci F, Moretto G, Candeago RM, et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto's encephalopathy. Neurology 2003; 60:712.</a></li><li><a class="nounderline abstract_t">Caselli RJ, Boeve BF, Scheithauer BW, et al. Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy. Neurology 1999; 53:1579.</a></li><li><a class="nounderline abstract_t">Josephs KA, Rubino FA, Dickson DW. Nonvasculitic autoimmune inflammatory meningoencephalitis. Neuropathology 2004; 24:149.</a></li><li><a class="nounderline abstract_t">Hoffman Snyder C, Mishark KJ, Caviness JN, et al. Nonvasculitic autoimmune inflammatory meningoencephalitis imitating Creutzfeldt-Jakob disease. Arch Neurol 2006; 63:766.</a></li><li><a class="nounderline abstract_t">Seo SW, Lee BI, Lee JD, et al. Thyrotoxic autoimmune encephalopathy: a repeat positron emission tomography study. J Neurol Neurosurg Psychiatry 2003; 74:504.</a></li><li><a class="nounderline abstract_t">Laurent C, Capron J, Quillerou B, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature. Autoimmun Rev 2016; 15:1129.</a></li><li><a class="nounderline abstract_t">Ferracci F, Bertiato G, Moretto G. Hashimoto's encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci 2004; 217:165.</a></li><li><a class="nounderline abstract_t">Ferracci F, Carnevale A. The neurological disorder associated with thyroid autoimmunity. J Neurol 2006; 253:975.</a></li><li><a class="nounderline abstract_t">Erol I, Saygi S, Alehan F. Hashimoto's encephalopathy in children and adolescents. Pediatr Neurol 2011; 45:420.</a></li><li><a class="nounderline abstract_t">Spiegel J, Hellwig D, Becker G, Müller M. Progressive dementia caused by Hashimoto's encephalopathy -- report of two cases. Eur J Neurol 2004; 11:711.</a></li><li><a class="nounderline abstract_t">Ferlazzo E, Raffaele M, Mazzù I, Pisani F. Recurrent status epilepticus as the main feature of Hashimoto's encephalopathy. Epilepsy Behav 2006; 8:328.</a></li><li><a class="nounderline abstract_t">McKeon A, McNamara B, Sweeney B. Hashimoto's encephalopathy presenting with psychosis and generalized absence status. J Neurol 2004; 251:1025.</a></li><li><a class="nounderline abstract_t">Mattozzi S, Sabater L, Escudero D, et al. Hashimoto encephalopathy in the 21st century. Neurology 2020; 94:e217.</a></li><li><a class="nounderline abstract_t">Marshall GA, Doyle JJ. Long-term treatment of Hashimoto's encephalopathy. J Neuropsychiatry Clin Neurosci 2006; 18:14.</a></li><li><a class="nounderline abstract_t">Vander T, Hallevy C, Alsaed I, et al. 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. J Neurol 2004; 251:1273.</a></li><li><a class="nounderline abstract_t">Passarella B, Negro C, Nozzoli C, et al. Cerebellar subacute syndrome due to corticosteroid-responsive encephalopathy associated with autoimmune thyroiditis (also called "Hashimoto's encephalopathy"). Clin Ter 2005; 156:13.</a></li><li><a class="nounderline abstract_t">Manto M, Goldman S, Bodur H. [Cerebellar syndrome associated with Hashimoto's encephalopathy]. Rev Neurol (Paris) 1996; 152:202.</a></li><li><a class="nounderline abstract_t">Taurin G, Golfier V, Pinel JF, et al. Choreic syndrome due to Hashimoto's encephalopathy. Mov Disord 2002; 17:1091.</a></li><li><a class="nounderline abstract_t">Selim M, Drachman DA. Ataxia associated with Hashimoto's disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis. J Neurol Neurosurg Psychiatry 2001; 71:81.</a></li><li><a class="nounderline abstract_t">Nakagawa H, Yoneda M, Fujii A, et al. Hashimoto's encephalopathy presenting with progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry 2007; 78:196.</a></li><li><a class="nounderline abstract_t">Cao NJ, Tselis AC, Li J, Gorman M. A case of Hashimoto's encephalopathy: association with sensory ganglionopathy. J Neurol Sci 2005; 238:105.</a></li><li><a class="nounderline abstract_t">Sheng B, Lau KK, Li HL, Cheng LF. A case of Hashimoto's encephalopathy with demyelinating peripheral neuropathy. Eur Neurol 2005; 53:84.</a></li><li><a class="nounderline abstract_t">Kastrup O, Maschke M, Schlamann K, Diener HC. Hashimoto encephalopathy and neuralgic amyotrophy--causal link or chance association? Eur Neurol 2005; 53:98.</a></li><li><a class="nounderline abstract_t">Hernández Echebarría LE, Saiz A, Graus F, et al. Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. Neurology 2000; 54:1539.</a></li><li><a class="nounderline abstract_t">Gayatri NA, Whitehouse WP. Pilot survey of Hashimoto's encephalopathy in children. Dev Med Child Neurol 2005; 47:556.</a></li><li><a class="nounderline abstract_t">Henchey R, Cibula J, Helveston W, et al. Electroencephalographic findings in Hashimoto's encephalopathy. Neurology 1995; 45:977.</a></li><li><a class="nounderline abstract_t">McCabe DJ, Burke T, Connolly S, Hutchinson M. Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto's encephalopathy. Neurology 2000; 54:737.</a></li><li><a class="nounderline abstract_t">Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63:197.</a></li><li><a class="nounderline abstract_t">Thrush DC, Boddie HG. Episodic encephalopathy associated with thyroid disorders. J Neurol Neurosurg Psychiatry 1974; 37:696.</a></li><li><a class="nounderline abstract_t">Maas A, Braun KP, Geleijns K, et al. Risks and Benefits of Rituximab in the Treatment of Hashimoto Encephalopathy in Children: Two Case Reports and a Mini Review. Pediatr Neurol 2017; 66:28.</a></li><li><a class="nounderline abstract_t">Jacob S, Rajabally YA. Hashimoto's encephalopathy: steroid resistance and response to intravenous immunoglobulins. J Neurol Neurosurg Psychiatry 2005; 76:455.</a></li><li><a class="nounderline abstract_t">Drulović J, Andrejević S, Bonaci-Nikolić B, Mijailović V. Hashimoto's encephalopathy: a long-lasting remission induced by intravenous immunoglobulins. Vojnosanit Pregl 2011; 68:452.</a></li><li><a class="nounderline abstract_t">Nieuwenhuis L, Santens P, Vanwalleghem P, Boon P. Subacute Hashimoto's encephalopathy, treated with plasmapheresis. Acta Neurol Belg 2004; 104:80.</a></li><li><a class="nounderline abstract_t">Nagpal T, Pande S. Hashimoto's encephalopathy: response to plasma exchange. Neurol India 2004; 52:245.</a></li><li><a class="nounderline abstract_t">Boers PM, Colebatch JG. Hashimoto's encephalopathy responding to plasmapheresis. J Neurol Neurosurg Psychiatry 2001; 70:132.</a></li><li><a class="nounderline abstract_t">Yu HJ, Lee J, Seo DW, Lee M. Clinical manifestations and treatment response of steroid in pediatric Hashimoto encephalopathy. J Child Neurol 2014; 29:938.</a></li></ol></div><div id="topicVersionRevision">Topic 4821 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4161638" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hashimoto's disease and encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8865025" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580699" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hashimoto encephalopathy: syndrome or myth?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023109" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992366" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers--report of 5 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581677" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hashimoto's encephalopathy: postmortem findings after fatal status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12871097" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto's encephalopathy (recurrent acute disseminated encephalomyelitis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158076" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hashimoto's encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885711" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : EEG changes in a patient with steroid-responsive encephalopathy associated with antibodies to thyroperoxidase (SREAT, Hashimoto's encephalopathy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15826922" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hashimoto's encephalopathy: myth or reality? An endocrinologist's perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10865094" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675602" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Anti-neuronal autoantibody in Hashimoto's encephalopathy: neuropathological, immunohistochemical, and biochemical analysis of two patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9270613" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Autoimmune thyroiditis and a rapidly progressive dementia: global hypoperfusion on SPECT scanning suggests a possible mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15833368" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto's encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15607202" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601119" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto's encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534272" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15139593" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Nonvasculitic autoimmune inflammatory meningoencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682549" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nonvasculitic autoimmune inflammatory meningoencephalitis imitating Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12640074" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Thyrotoxic autoimmune encephalopathy: a repeat positron emission tomography study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27639840" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706219" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hashimoto's encephalopathy: epidemiologic data and pathogenetic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16786216" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The neurological disorder associated with thyroid autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22115010" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hashimoto's encephalopathy in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15469458" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Progressive dementia caused by Hashimoto's encephalopathy -- report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16343998" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recurrent status epilepticus as the main feature of Hashimoto's encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316812" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hashimoto's encephalopathy presenting with psychosis and generalized absence status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31882532" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hashimoto encephalopathy in the 21st century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16525066" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term treatment of Hashimoto's encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15503111" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080655" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cerebellar subacute syndrome due to corticosteroid-responsive encephalopathy associated with autoimmune thyroiditis (also called "Hashimoto's encephalopathy").</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8761631" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : [Cerebellar syndrome associated with Hashimoto's encephalopathy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360567" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Choreic syndrome due to Hashimoto's encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11413268" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ataxia associated with Hashimoto's disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229749" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hashimoto's encephalopathy presenting with progressive cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139308" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A case of Hashimoto's encephalopathy: association with sensory ganglionopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855775" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A case of Hashimoto's encephalopathy with demyelinating peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855782" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hashimoto encephalopathy and neuralgic amyotrophy--causal link or chance association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10751278" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16108457" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pilot survey of Hashimoto's encephalopathy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7746418" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Electroencephalographic findings in Hashimoto's encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10680814" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto's encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476807" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Steroid-responsive encephalopathy associated with autoimmune thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4135819" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Episodic encephalopathy associated with thyroid disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789116" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Risks and Benefits of Rituximab in the Treatment of Hashimoto Encephalopathy in Children: Two Case Reports and a Mini Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716552" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hashimoto's encephalopathy: steroid resistance and response to intravenous immunoglobulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21739914" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hashimoto's encephalopathy: a long-lasting remission induced by intravenous immunoglobulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15508271" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Subacute Hashimoto's encephalopathy, treated with plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269483" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hashimoto's encephalopathy: response to plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11118266" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hashimoto's encephalopathy responding to plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24056154" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical manifestations and treatment response of steroid in pediatric Hashimoto encephalopathy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
